Lynparza misses in Asian gastric cancer study

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Lynparza olaparib plus paclitaxel missed the primary endpoint of overall survival vs. paclitaxel alone in the Phase III GOLD trial to treat advanced HER2-negative gastric cancer in patients who progressed following first-line therapy.

The pharma said there was a numerical but non-significant survival trend in the group receiving the poly(ADP-ribose) polymerase ( PARP) inhibitor. The study enrolled 525 patients in China, Japan, South Korea and Taiwan. AZ plans to present detailed data at an upcoming medical meeting. ...